- Home
- CALM vs MRUS Comparison
CALM vs MRUS Comparison
Compare CALM & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALM
- MRUS
- Stock Information
- Founded
- CALM 1957
- MRUS 2003
- Country
- CALM United States
- MRUS Netherlands
- Employees
- CALM N/A
- MRUS N/A
- Industry
- CALM Farming/Seeds/Milling
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- CALM Consumer Staples
- MRUS Health Care
- Exchange
- CALM Nasdaq
- MRUS Nasdaq
- Market Cap
- CALM 4.9B
- MRUS 4.1B
- IPO Year
- CALM 1996
- MRUS 2016
- Fundamental
- Price
- CALM $105.94
- MRUS $63.26
- Analyst Decision
- CALM Sell
- MRUS Strong Buy
- Analyst Count
- CALM 3
- MRUS 13
- Target Price
- CALM $86.67
- MRUS $88.54
- AVG Volume (30 Days)
- CALM 791.5K
- MRUS 603.8K
- Earning Date
- CALM 07-22-2025
- MRUS 07-31-2025
- Dividend Yield
- CALM 1.79%
- MRUS N/A
- EPS Growth
- CALM 258.93
- MRUS N/A
- EPS
- CALM 20.24
- MRUS N/A
- Revenue
- CALM $3,799,016,000.00
- MRUS $54,732,000.00
- Revenue This Year
- CALM $76.88
- MRUS $68.08
- Revenue Next Year
- CALM N/A
- MRUS $0.09
- P/E Ratio
- CALM $5.22
- MRUS N/A
- Revenue Growth
- CALM 60.00
- MRUS 42.77
- 52 Week Low
- CALM $63.37
- MRUS $33.19
- 52 Week High
- CALM $116.41
- MRUS $63.43
- Technical
- Relative Strength Index (RSI)
- CALM 64.42
- MRUS 74.17
- Support Level
- CALM $98.31
- MRUS $54.09
- Resistance Level
- CALM $105.82
- MRUS $56.60
- Average True Range (ATR)
- CALM 2.74
- MRUS 1.97
- MACD
- CALM 0.33
- MRUS 0.77
- Stochastic Oscillator
- CALM 81.34
- MRUS 98.54
About CALM Cal-Maine Foods Inc.
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.